Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

small-cap

One Pharmaceuticals Stock Trading Near Resistance Levels – EZZ

Oct 13, 2025 | Team Kalkine
One Pharmaceuticals Stock Trading Near Resistance Levels – EZZ
Image source: shutterstock

  • EZZ:ASX
  • Investment Type
    Small-Cap
  • Risk Level
  • Action
  • Rec. Price (AU$)

This report is an updated version of the report published on 13 October 2025 at 1:01 PM AEDT.

EZZ Life Science Holdings Limited (ASX: EZZ)  

EZZ Life Science Holdings Limited (ASX: EZZ) is an Australian genomic life science company. The company’s principal activity is the formulation, production, marketing and sale of the ezz branded health supplements to retailers and consumers domestically and internationally.

Recommendation Rationale – SELL at AUD 2.800

  • Trading Near Resistance Level: EZZ’s share price has surpassed its R2 level, recommended on 26 September 2025. Therefore, share price can face resistance at the current levels.
  • Technical Commentary: On the daily chart, EZZ’s stock price is approaching a significant resistance after a rally, anticipating a potential correction. Moreover, the momentum oscillator RSI (14-period) is reversing from its overbought territory, providing more evidence to the previous observation. Prices are trading above both 21-day and 50-day SMAs, which might function as dynamic support levels for the stock; in contrast, the stock’s next round level might act as a sentimental resistance. A significant support level for the stock is located at AUD 2.35, while critical resistance level is placed at AUD 3.00.
  • Decline in Profits & Cash Inflows: The company’s profit fell 3.3% year-on-year to AUD 6.73 million in FY25, while net cash from operating activities dropped 29.2% YoY to AUD 4.35 million.
  • Emerging Risks: Risks associated with product innovation and market expansion, including the potential that new products or geographic ventures may fall short of expectations or fail to meet regulatory standards. Heightened competition and regulatory challenges in the fast-growing health supplement and personal care markets across Asia-Pacific, the U.S., and Southeast Asia could limit growth and compress margins.

EZZ Daily Chart

Considering that the stock has surpassed its R2 level, macroeconomic uncertainty, share price movement, current trading level, and risks associated, the share price can face consolidation at the current levels. Hence, a ‘Sell’ recommendation is given on the stock at the current market price of AUD 2.800, at 11:55 AM AEDT, as of 13 October 2025.

Note: This report may be updated with details around fundamental and technical analysis, price/ chart in due course, as appropriate. 

Note 1: Past performance is neither an indicator nor a guarantee of future performance.

Note 2: The reference date for all price data, currency, technical indicators, support, and resistance levels is 13 October 2025. The reference data in this report has been partly sourced from REFINITIV.

Note 3: Investment decisions should be made depending on an individual's appetite for upside potential, risks, holding duration, and any previous holdings. An 'Exit' from the stock can be considered if the Target Price mentioned as per the Valuation and or the technical levels provided has been achieved and is subject to the factors discussed above.    

Note 4: Kalkine reports are prepared based on the stock prices captured either from REFINITIV or Trading View. Typically, REFINITIV or Trading View may reflect stock prices with a delay which could be a lag of 25-30 minutes. There can be no assurance that future results or events will be consistent with the information provided in the report. The information is subject to change without any prior notice. 

Technical Indicators Defined: - 

Support: A level at which the stock prices tend to find support if they are falling, and a downtrend may take a pause backed by demand or buying interest. Support 1 refers to the nearby support level for the stock and if the price breaches the level, then Support 2 may act as the crucial support level for the stock.

Resistance: A level at which the stock prices tend to find resistance when they are rising, and an uptrend may take a pause due to profit booking or selling interest. Resistance 1 refers to the nearby resistance level for the stock and if the price surpasses the level, then Resistance 2 may act as the crucial resistance level for the stock.

Stop-loss: It is a level to protect further losses in case of unfavourable movement in the stock prices.


Disclaimer-

This report (“Report”) has been issued by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and prepared by Kalkine and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any advice provided in this Report is general advice only and does not take into account your objectives, financial situation or needs. You should therefore consider whether the advice is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred in this Report. You should obtain a copy of the relevant Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any of the general advice in this Report or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Report and on the Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its reports (including this Report), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Report does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products. Our reports contain general recommendations to invest in securities and other financial products. Kalkine is not responsible for, and does not guarantee, the performance of, or returns on, any investments mentioned in this Report.

Kalkine does not issue, sell or deal in any financial products.

This Report may contain information on past performance of particular investments. Past performance is not a reliable indicator of future performance. Returns stated do not take into account transaction costs and taxes. To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Report, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you.  To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information. Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Report or on the Kalkine website. Any such employees and associates are required to comply with certain, procedures and disclosures as required by law.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website including entities covered in this Report.

Copyright 2025 Krish Capital Pty. Ltd. (ABN 61629651510). All Rights Reserved. No part of this report, or its content, may be reproduced in any form without our prior consent.

Past performance is not a reliable indicator of future performance.

Support

Hi! How can we help you today?

Loading…